XNAS · FLNA
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Filana Therapeutics, Inc. Common Stock

Filana Therapeutics, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$1.23
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is FLNA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Filana Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2000
Employees
20
Country
US

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.23
Last session
Day high
$1.23
Last session
Day low
$1.23
Last session
Previous close
$1.23
52W high
$1.32
-6.82% from high
52W low
$1.17
40% of range
Market cap
$59.4M
EPS
$-0.2100
Shares out
48.3M
VWAP
$1.23
Last session
Price history computed in-house
1W
+1.65%
SMA 50 $1.23 · above
SMA 200 $1.23 · above
52W position 40%
Veridion warehouse edge

Warehouse intelligence for FLNA.

Veridion Score
81
0: 941: 572: 323: 904: 795: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

FLNA insider activity

Filana Therapeutics, Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for FLNA.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

FLNA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for FLNA in this window.
Lobbying spend

FLNA lobbying filings, year to date.

Registered lobbying filings matched to Filana Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for FLNA in this window.
Latest news · FLNA
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for FLNA.
Options
Sovereign unlock shows live options positioning for FLNA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.